We are delighted to let you know that our friends at Sydney Children’s Hospital in Randwick are now recruiting for the TSC-STEPS research trial (formerly known as STOP2).
The purpose of this ground-breaking research is to learn more about the safety and efficacy of early sirolimus treatment to prevent or delay seizure onset in infants diagnosed with TSC. Infants 0 to 6 months old who are diagnosed with TSC and have no history of seizures may be eligible to participate.
If needed, TSA can offer some assistance with travel and accommodation costs for families outside of Sydney, including interstate families who participate in the trial.
What
The purpose of this research study is to learn more about the safety and efficacy of early sirolimus treatment to prevent or delay seizure onset in infants diagnosed with Tuberous Sclerosis Complex (SC), a genetic disorder where epilepsy is common.
Who
Infants 0 to 6 months old who are diagnosed with TSC and have no history of seizures may be eligible to participate
Compensation
There is no compensation for your participation in this study. However, there may be limited travel funding available if you do not live in NSW.
Details
For more information, visit: www.clinicaltrials.gov (identifier NCT05104983)
Or contact:
Dr Denise Chan
102\9382 5523